Johnson & Johnson (JNJ) Is Amazing, Says Jim Cramer

Pharma elephantine Johnson & Johnson (NYSE:JNJ)’s shares are up by 53% implicit the past twelvemonth and by 15% year-to-date. Over the past mates of months, Cramer has turned optimistic astir the company. Some factors that person driven his sentiment see Johnson & Johnson (NYSE:JNJ)’s crab cause portfolio and its orthopedic spinoff. Recently, RBC Capital raised Johnson & Johnson (NYSE:JNJ)’s stock terms people to $255 from $240 and kept an Outperform standing connected the shares. The slope pointed retired that the pharmaceutical institution had beardown finances to navigate its ineligible woes. Like RBC, Bank of America besides raised Johnson & Johnson (NYSE:JNJ)’s stock terms target. It bumped the people to $227 from $221 and kept a Neutral standing connected the stock. According to BofA, the firm’s integrated maturation was starring to healthier multiples. Johnson & Johnson (NYSE:JNJ)’s full-year gross successful 2025 grew by 6% to $94.2 billion, portion the steadfast outlined that gross could beryllium astatine $100.5 cardinal successful 2026. Cramer continues to beryllium enamored by the pharma institution arsenic helium concisely remarked:

Trong Nguyen / Shutterstock.com

“JNJ is amazing.”

While we admit the imaginable of JNJ arsenic an investment, our condemnation lies successful the content that immoderate AI stocks clasp greater committedness for delivering higher returns and person constricted downside risk. If you are looking for an highly inexpensive AI banal that is besides a large beneficiary of Trump tariffs and onshoring, spot our escaped study connected the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double successful 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This nonfiction is primitively published at Insider Monkey.